{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:00:14Z","timestamp":1747198814865,"version":"3.40.5"},"reference-count":10,"publisher":"Vilnius University Press","issue":"2","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AML"],"abstract":"<jats:p>5-Aminosalicylic acid (5-ASA) preparations are widely used in the treatment of inflammatory bowel diseases. The most commonly used medicine is mesalamine. Overall, it is a very safe drug with few side effects. A rare side effect of this medicine is interstitial nephritis (IN). With discontinuation of the drug the renal function usually restores. However, if damage has not been detected for a long time, irreversible changes may occur. In this article, we present a clinical case of mesalamine induced IN. A 56-year-old man who has had ulcerative colitis for 20 years, was admitted due to mesalamine induced acute renal failure. A year before, the patient had been diagnosed with mesalamine-induced interstitial nephritis and the treatment with mesalamine was discontinued. The symptoms of ulcerative colitis worsened, and the patient independently decided to start taking mesalamine, which resulted in worsening of his health condition and impaired renal function. Mesalamine has been discontinued, additional treatment for acute kidney failure has been administered including hemodialysis. Renal function recovered and the patient was released for further treatment of ulcerative colitis and monitoring of renal function.<\/jats:p>","DOI":"10.15388\/amed.2021.28.2.14","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T14:31:46Z","timestamp":1636381906000},"page":"14","source":"Crossref","is-referenced-by-count":0,"title":["Drug-Induced Intersticial Nephritis. Clinical Case"],"prefix":"10.15388","volume":"28","author":[{"given":"Paulina","family":"Tekoriut\u0117","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Matuliauskait\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9086-3675","authenticated-orcid":false,"given":"Laimas Virginijus","family":"Jonaitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6097","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel J. Ulcerative colitis. Lancet 2017 -4-29;389(10080):1756-1770. DOI: 10.1016\/S0140-6736(16)32126-2","DOI":"10.1016\/S0140-6736(16)32126-2"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clinic proceedings 2019 Jul;94(7):1357-1373. DOI: 10.1016\/j.mayocp.2019.01.018","DOI":"10.1016\/j.mayocp.2019.01.018"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Corica D, Romano C. Renal Involvement in Inflammatory Bowel Diseases. J Crohns Colitis 2016 -02;10(2):226-235. DOI: 10.1093\/ecco-jcc\/jjv138","DOI":"10.1093\/ecco-jcc\/jjv138"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Van Staa TP, Travis S, Leufkens HGM, Logan RF. 5-aminosalicylic acids and the risk of renal disease: A large British epidemiologic study. Gastroenterology 2004 June 1,;126(7):1733-1739. DOI: 10.1053\/j.gastro.2004.03.016","DOI":"10.1053\/j.gastro.2004.03.016"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Shah J, Dutta U, Das A, Sharma V, Mandavdhare H, Sharma P, et al. Relationship between Mayo endoscopic score and histological scores in ulcerative colitis: A prospective study. JGH open 2020 Jun;4(3):382-386. DOI: 10.1002\/jgh3.12260","DOI":"10.1002\/jgh3.12260"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Sairenji T, Collins KL, Evans DV. An Update on Inflammatory Bowel Disease. Prim Care 2017 -12;44(4):673-692.","DOI":"10.1016\/j.pop.2017.07.010"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Adiga A, Goldfarb DS. The Association of Mesalamine With Kidney Disease. Adv Chronic Kidney Dis 2020 -01;27(1):72-76. DOI: 10.1053\/j.ackd.2019.09.002","DOI":"10.1053\/j.ackd.2019.09.002"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Corrigan G, Stevens PE. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2000 -01;14(1):1-6. DOI: 10.1046\/j.1365-2036.2000.00683.x","DOI":"10.1046\/j.1365-2036.2000.00683.x"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Heap GA, So K, Weedon M, Edney N, Bewshea C, Singh A, et al. Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis 2016 -02;10(2):149-158. DOI: 10.1093\/ecco-jcc\/jjv219","DOI":"10.1093\/ecco-jcc\/jjv219"},{"key":"ref9","unstructured":"Drug Interactions Checker - Medscape Drug Reference Database. Available at: https:\/\/reference.medscape.com\/drug-interactionchecker"}],"container-title":["Acta medica Lituanica"],"original-title":[],"link":[{"URL":"https:\/\/www.journals.vu.lt\/AML\/article\/download\/24614\/24276","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journals.vu.lt\/AML\/article\/download\/24614\/24277","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journals.vu.lt\/AML\/article\/download\/24614\/24276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T14:33:03Z","timestamp":1636381983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journals.vu.lt\/AML\/article\/view\/24614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,7,29]]}},"URL":"https:\/\/doi.org\/10.15388\/amed.2021.28.2.14","relation":{},"ISSN":["2029-4174","1392-0138"],"issn-type":[{"type":"electronic","value":"2029-4174"},{"type":"print","value":"1392-0138"}],"subject":[],"published":{"date-parts":[[2021,11,8]]}}}